186 related articles for article (PubMed ID: 30311243)
1. Quantifying the association between progression-free survival and overall survival in oncology trials using Kendall's τ.
Weber EM; Titman AC
Stat Med; 2019 Feb; 38(5):703-719. PubMed ID: 30311243
[TBL] [Abstract][Full Text] [Related]
2. Assessing temporal agreement between central and local progression-free survival times.
Zeng D; Cornea E; Dong J; Pan J; Ibrahim JG
Stat Med; 2015 Feb; 34(5):844-58. PubMed ID: 25393731
[TBL] [Abstract][Full Text] [Related]
3. On the association between variables with lower detection limits.
Romdhani H; Lakhal-Chaieb L
Stat Med; 2011 Nov; 30(26):3137-48. PubMed ID: 21898520
[TBL] [Abstract][Full Text] [Related]
4. Conditional copula models for correlated survival endpoints: Individual patient data meta-analysis of randomized controlled trials.
Emura T; Sofeu CL; Rondeau V
Stat Methods Med Res; 2021 Dec; 30(12):2634-2650. PubMed ID: 34632882
[TBL] [Abstract][Full Text] [Related]
5. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.
Foster NR; Renfro LA; Schild SE; Redman MW; Wang XF; Dahlberg SE; Ding K; Bradbury PA; Ramalingam SS; Gandara DR; Shibata T; Saijo N; Vokes EE; Adjei AA; Mandrekar SJ
J Thorac Oncol; 2015 Jul; 10(7):1099-106. PubMed ID: 26134227
[TBL] [Abstract][Full Text] [Related]
6. Inverse probability of censoring weighted estimates of Kendall's τ for gap time analyses.
Lakhal-Chaieb L; Cook RJ; Lin X
Biometrics; 2010 Dec; 66(4):1145-52. PubMed ID: 20337629
[TBL] [Abstract][Full Text] [Related]
7. Archimedean copula model selection under dependent truncation.
Beaudoin D; Lakhal-Chaieb L
Stat Med; 2008 Sep; 27(22):4440-54. PubMed ID: 18551531
[TBL] [Abstract][Full Text] [Related]
8. A joint frailty-copula model for meta-analytic validation of failure time surrogate endpoints in clinical trials.
Sofeu CL; Emura T; Rondeau V
Biom J; 2021 Feb; 63(2):423-446. PubMed ID: 33006170
[TBL] [Abstract][Full Text] [Related]
9. surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials.
Rotolo F; Paoletti X; Michiels S
Comput Methods Programs Biomed; 2018 Mar; 155():189-198. PubMed ID: 29512498
[TBL] [Abstract][Full Text] [Related]
10. Joint modeling of progression-free survival and death in advanced cancer clinical trials.
Dejardin D; Lesaffre E; Verbeke G
Stat Med; 2010 Jul; 29(16):1724-34. PubMed ID: 20572123
[TBL] [Abstract][Full Text] [Related]
11. Association measures for bivariate failure times in the presence of a cure fraction.
Lakhal-Chaieb L; Duchesne T
Lifetime Data Anal; 2017 Oct; 23(4):517-532. PubMed ID: 27339474
[TBL] [Abstract][Full Text] [Related]
12. Joint modeling of progression-free and overall survival and computation of correlation measures.
Meller M; Beyersmann J; Rufibach K
Stat Med; 2019 Sep; 38(22):4270-4289. PubMed ID: 31273817
[TBL] [Abstract][Full Text] [Related]
13. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
Wang X; Wang X; Hodgson L; George SL; Sargent DJ; Foster NR; Ganti AK; Stinchcombe TE; Crawford J; Kratzke R; Adjei AA; Kindler HL; Vokes EE; Pang H
Oncologist; 2017 Feb; 22(2):189-198. PubMed ID: 28188257
[TBL] [Abstract][Full Text] [Related]
14. Identification of Gene-Environment Interactions by Non-Parametric Kendall's Partial Correlation with Application to TCGA Ultrahigh-Dimensional Survival Genomic Data.
Wang JH; Yang CT
Front Biosci (Landmark Ed); 2022 Jul; 27(8):225. PubMed ID: 36042165
[TBL] [Abstract][Full Text] [Related]
15. Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework.
Nomura S; Hirakawa A; Hamada C
J Biopharm Stat; 2018; 28(4):589-611. PubMed ID: 28886305
[TBL] [Abstract][Full Text] [Related]
16. Serial association analyses of recurrent gap time data via Kendall's tau.
Fu TC; Su DH; Chang SH
Biostatistics; 2016 Jan; 17(1):188-202. PubMed ID: 26395906
[TBL] [Abstract][Full Text] [Related]
17. Eliminating bias due to censoring in Kendall's tau estimators for quasi-independence of truncation and failure.
Austin MD; Betensky RA
Comput Stat Data Anal; 2014 May; 73():16-26. PubMed ID: 24505164
[TBL] [Abstract][Full Text] [Related]
18. Design of cancer trials based on progression-free survival with intermittent assessment.
Zeng L; Cook RJ; Lee KA
Stat Med; 2018 May; 37(12):1947-1959. PubMed ID: 29582452
[TBL] [Abstract][Full Text] [Related]
19. Conditional independence test by generalized Kendall's tau with generalized odds ratio.
Ji S; Ning J; Qin J; Follmann D
Stat Methods Med Res; 2018 Nov; 27(11):3224-3235. PubMed ID: 29298614
[TBL] [Abstract][Full Text] [Related]
20. Gene selection for survival data under dependent censoring: A copula-based approach.
Emura T; Chen YH
Stat Methods Med Res; 2016 Dec; 25(6):2840-2857. PubMed ID: 24821000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
